









Markets
/
Stocks
/
nasdaq-notv
/

Inotiv Inc

NOTV

1.370USD

-0.080-5.52%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

47.07MMarket Cap

LossP/E TTM



Inotiv Inc

1.370

-0.080-5.52%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a strong stock market performance and outperforming fundamentals, the technicals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

154 / 506

Overall Ranking

264 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 3 analysts

Buy

Current Rating

5.500

Target Price

+279.31%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Inotiv, Inc. is a contract research company, which is engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DSA segment supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. The RMS segment offer access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.

Fairly Valued

The company’s latest PE is -0.52, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 12.88M shares, decreasing 24.02% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 1.38M shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 7.64, which is higher than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 130.68M, representing a year-over-year increase of 23.54%, while its net profit experienced a year-over-year increase of 32.62%.

Score

Industry at a Glance

Previous score

7.64

Change



Financials

4.37

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.25

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

9.12

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.47

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -0.55, which is -17.34% below the recent high of -0.46 and -44.48% above the recent low of -0.80.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 154/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 7.33, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Inotiv Inc is 5.00, with a high of 9.00 and a low of 2.50.

Score

Industry at a Glance

Previous score

7.33

Change

Support & Resistance

No Data

Analyst Rating

Based on 3 analysts

Buy

Current Rating

5.500

Target Price

+279.31%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Inotiv Inc

NOTV

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 5.73, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 1.81 and the support level at 1.18, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.73

Change

-0.18

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.013

Sell

RSI(14)

36.881

Neutral

STOCH(KDJ)(9,3,3)

30.690

Neutral

ATR(14)

0.128

Low Volatility

CCI(14)

-46.066

Neutral

Williams %R

74.863

Sell

TRIX(12,20)

-1.216

Sell

StochRSI(14)

61.353

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.374

Sell

MA10

1.432

Sell

MA20

1.562

Sell

MA50

1.800

Sell

MA100

2.007

Sell

MA200

2.764

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 37.49%, representing a quarter-over-quarter increase of 0.61%. The largest institutional shareholder is The Vanguard, holding a total of 1.38M shares, representing 4.03% of shares outstanding, with 24.87% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Balyasny Asset Management LP

1.27M

-2.59%

The Vanguard Group, Inc.

Star Investors

1.29M

+18.80%

Jermyn Street Associates, L.L.C.

1.26M

-8.58%

Leasure (Robert Jr.)

1.24M

+52.90%

Sagartz (John E)

708.32K

+4.42%

Hardy (Adrian)

400.78K

+6.65%

Renaissance Technologies LLC

Star Investors

184.06K

-39.50%

Massar Capital Management, LP

150.00K

Vantage Point Financial, LLC.

336.55K

Geode Capital Management, L.L.C.

328.48K

+38.10%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.04, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 4.20. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.